Autoimmune Myocarditis, Old Dogs and New Tricks
Taejoon Won,Evelyn J. Song,Hannah M. Kalinoski,Javid J. Moslehi,Daniela Čiháková
DOI: https://doi.org/10.1161/circresaha.124.323816
IF: 23.213
2024-06-08
Circulation Research
Abstract:Circulation Research, Volume 134, Issue 12, Page 1767-1790, June 7, 2024. Autoimmunity significantly contributes to the pathogenesis of myocarditis, underscored by its increased frequency in autoimmune diseases such as systemic lupus erythematosus and polymyositis. Even in cases of myocarditis caused by viral infections, dysregulated immune responses contribute to pathogenesis. However, whether triggered by existing autoimmune conditions or viral infections, the precise antigens and immunologic pathways driving myocarditis remain incompletely understood. The emergence of myocarditis associated with immune checkpoint inhibitor therapy, commonly used for treating cancer, has afforded an opportunity to understand autoimmune mechanisms in myocarditis, with autoreactive T cells specific for cardiac myosin playing a pivotal role. Despite their self-antigen recognition, cardiac myosin-specific T cells can be present in healthy individuals due to bypassing the thymic selection stage. In recent studies, novel modalities in suppressing the activity of pathogenic T cells including cardiac myosin-specific T cells have proven effective in treating autoimmune myocarditis. This review offers an overview of the current understanding of heart antigens, autoantibodies, and immune cells as the autoimmune mechanisms underlying various forms of myocarditis, along with the latest updates on clinical management and prospects for future research.
cardiac & cardiovascular systems,peripheral vascular disease,hematology